A1 Refereed original research article in a scientific journal

Increased intracranial pressure in severe traumatic axonal injury patients - A retrospective single-center study




AuthorsWesterberg, Gustaf; Hossain, Iftakher; Drake, Mattias; Tsitsopoulos, Parmenion P.; Marklund, Niklas

PublisherElsevier

Publication year2026

Journal: Brain and Spine

Article number105945

Volume6

eISSN2772-5294

DOIhttps://doi.org/10.1016/j.bas.2026.105945

Publication's open availability at the time of reportingOpen Access

Publication channel's open availability Open Access publication channel

Web address https://doi.org/10.1016/j.bas.2026.105945

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/515738890

Self-archived copy's licenceCC BY NC ND

Self-archived copy's versionPublisher`s PDF


Abstract

Introduction: Traumatic axonal injury (TAI), often caused by rapid rotational forces and high-energy accidents, is common in severe traumatic brain injury (sTBI). The intracranial pressure (ICP) dynamics are often unpredictable, and the need for ICP monitoring remains debated.
Research question: What is the incidence of ICP elevation in patients with TAI, and how often is escalated ICP-lowering treatment required?
Material and methods: Retrospectively, sTBI patients treated between 2007 and 2022 with TAI lesions at the grey–white matter interface, corpus callosum, deep central structures, and/or brainstem, on magnetic resonance imaging (MRI) were included. Patients with ICP elevation despite baseline management were treated according to the Lund Concept, including beta-blockers, clonidine, and albumin. Decompressive craniectomy (DC) or high-dose barbiturate infusion was reserved for refractory ICP elevation.
Results: Thirty-one TAI patients (15 women and 16 men) presented with a median Glasgow Coma Scale motor score of 2 (range 1–6). All patients had TAI lesion in the grey-white interface, 27 patients also in the corpus callosum, and 16 patients had brainstem lesions. Elevated ICP was observed in 16 patients (52 %), of whom 4/16 (25 %) received either DC (n = 2), high-dose barbiturates (n = 1) or both (n = 1).
Discussion and conclusion: The risk of increased ICP in TAI patients has been debated. Our present results, showing that 52 % of TAI patients experienced elevated ICP requiring escalated ICP-lowering strategies, argue that ICP monitoring is required in TAI. The impact of increased ICP on outcome following TAI should be explored in future studies.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Funding information in the publication
The authors thank the following foundations for the research funding. The Finnish Medical Foundation (IH), The Päivikki and Sakari Sohlberg Foundation (IH), The Paulo Foundation (IH), The Orion Research Foundation (IH), State Research Funding of Finland (IH), The Finnish Cultural Foundation (IH), Skåne University Hospital ALF funds (NM), Hans-Gabriel af Trolle Wachtmeister Foundation (NM) and Swedish Brain Foundation (NM).


Last updated on 11/03/2026 03:05:22 PM